Merck's next-gen Gardasil wins FDA approval

What's better for Merck ($MRK) than the world's second-best-selling shot? A brand-new and more effective version of that product. Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration. Report